Value
5.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 5.0 |
QURE · Why this verdict
Why uniQure (QURE) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
uniQure is a gene therapy biotechnology company with reported revenue growth of 127% year-over-year and analyst consensus implying 40% upside to $34.01, but a cash burn rate of -573% of revenue, a quality score of 1.8 out of 10, and operating margin compression signal that the growth is not yet converting into sustainable financial performance.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The data flags two value-trap signals: revenue declined -11.6% year-over-year in one measure while operating margin sits at just 1.5%, indicating the company is at risk of consuming its asset base faster than it creates value, which is a classic precursor to dilutive financing rounds. Warnings | Operating margins improve above 10% within the next 4 reporting quarters as revenue scales. | →Stable |
| CounterAn operating margin of 1.5% in a gene therapy company nearing commercial launch can reflect deliberate investment in manufacturing and sales infrastructure rather than structural inefficiency. | ||
The company has delivered 127% year-over-year revenue growth, an extraordinary rate for a clinical-stage biotech that suggests commercial progress with an approved or late-stage gene therapy program is accelerating faster than analyst expectations. Growth breakdown | Revenue growth remains above 50% year-over-year for at least 2 consecutive reporting periods. | →Stable |
| CounterThe underlying data also flags declining revenue of -11.6% year-over-year in the bear case notes, indicating the 127% growth figure may reflect a one-time milestone payment or licensing event rather than recurring commercial revenue. | ||
With free cash flow at -573% of revenue and a quality score of 1.8 out of 10, the company is spending nearly six dollars in cash for every dollar of revenue, meaning it requires continuous equity or debt financing to survive. Quality breakdown | Cash burn improves to below -300% of revenue within 12 months as commercial revenue scales. | →Stable |
| CounterGene therapy companies at the commercialization inflection point often see rapid burn rate improvement once a product crosses the revenue ramp threshold, which the 127% growth rate may be signaling. | ||
The analyst consensus price target of $34.01 against a current price of $27.87 implies 22% upside with a reward-to-risk ratio of 3.14, and analysts rate the stock positively with an average score of 7.04 out of 10. Targets | The stock price rises above $33 within 12 months as commercial milestones reduce the discount applied by the market. | →Stable |
| CounterThree of the last four quarters produced earnings misses, including a -59.8% miss in November 2025, and analyst consensus can remain disconnected from price reality for extended periods in high-volatility biotech stocks. | ||
The data flags two value-trap signals: revenue declined -11.6% year-over-year in one measure while operating margin sits at just 1.5%, indicating the company is at risk of consuming its asset base faster than it creates value, which is a classic precursor to dilutive financing rounds.
→StableWarnings
- Expectation
- Operating margins improve above 10% within the next 4 reporting quarters as revenue scales.
CounterAn operating margin of 1.5% in a gene therapy company nearing commercial launch can reflect deliberate investment in manufacturing and sales infrastructure rather than structural inefficiency.
The company has delivered 127% year-over-year revenue growth, an extraordinary rate for a clinical-stage biotech that suggests commercial progress with an approved or late-stage gene therapy program is accelerating faster than analyst expectations.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 50% year-over-year for at least 2 consecutive reporting periods.
CounterThe underlying data also flags declining revenue of -11.6% year-over-year in the bear case notes, indicating the 127% growth figure may reflect a one-time milestone payment or licensing event rather than recurring commercial revenue.
With free cash flow at -573% of revenue and a quality score of 1.8 out of 10, the company is spending nearly six dollars in cash for every dollar of revenue, meaning it requires continuous equity or debt financing to survive.
→StableQuality breakdown
- Expectation
- Cash burn improves to below -300% of revenue within 12 months as commercial revenue scales.
CounterGene therapy companies at the commercialization inflection point often see rapid burn rate improvement once a product crosses the revenue ramp threshold, which the 127% growth rate may be signaling.
The analyst consensus price target of $34.01 against a current price of $27.87 implies 22% upside with a reward-to-risk ratio of 3.14, and analysts rate the stock positively with an average score of 7.04 out of 10.
→StableTargets
- Expectation
- The stock price rises above $33 within 12 months as commercial milestones reduce the discount applied by the market.
CounterThree of the last four quarters produced earnings misses, including a -59.8% miss in November 2025, and analyst consensus can remain disconnected from price reality for extended periods in high-volatility biotech stocks.
Per-dimension breakdown
Quality
1.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.2 |
| Piotroski F | 3.3 |
- ▸Cash-burning: FCF -573% of revenue
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 3/9
- ▸Quality concerns
Growth
10.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
- ▸Strong growth: 127% YoY
Momentum
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.2 |
| MACD | 10.0 |
| OBV | 1.0 |
| MA position | 9.0 |
| Volume | 7.7 |
- ▸Overbought (RSI 76)
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.1/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 5.4 |
| Analyst rating | 8.3 |
| Price target | 7.6 |
Insider
3.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.0 |
- ▸Notable insider selling — $12,355,678 (0.399% of mkt cap)
Peer rank
3.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 8.9 |
- ▸Industry growth leader
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.4 |
| support resistance | 0.5 |
| 52w position | 3.7 |
| gap | 5.0 |
Risk (lower is worse)
3.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.7 |
| days to cover | 5.2 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 0.0 |
| beta | 7.0 |
| debt equity | 1.3 |
| news risk | 3.0 |
- ▸High short interest justified: 18%
- ▸High IV: 98%
Catalyst
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 3.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- MOMENTUM:6.4>=5.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:35d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:0.3<1.5@spot
Warning (0)
none
Reward-to-Risk
0.27
Upside
+4.0%
Downside
15.0%
Sizing output
AVOID
SetupRECOVERY — Death cross but MACD improving, RSI 76
EdgeNO_EDGE — No clear edge identified
SuitabilityAGGRESSIVE — MCap $3.1B<$5B
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Growth at 10.0 could not lift the engine output above the verdict floor. Failed gate signal: ASYMMETRY:0.3<1.5@spot.
The strongest dimensions are Growth at 10.0, Sentiment at 7.1, and Momentum at 6.4; the weakest are Quality at 1.8, Technical at 2.4, and Insider at 3.3. The V9 engine flagged 1 failed gate, producing an asymmetric reward-to-risk of 0.27 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1The company has delivered 127% year-over-year revenue growth, an extraordinary rate for a clinical-stage biotech that suggests commercial progress with an approved or late-stage gene therapy program is accelerating faster than analyst expectations.
Trip ifRevenue growth falls below 30% year-over-year in any reported period.
- P2With free cash flow at -573% of revenue and a quality score of 1.8 out of 10, the company is spending nearly six dollars in cash for every dollar of revenue, meaning it requires continuous equity or debt financing to survive.
Trip ifCash burn worsens beyond -800% of revenue in any reported period.
- P3The analyst consensus price target of $34.01 against a current price of $27.87 implies 22% upside with a reward-to-risk ratio of 3.14, and analysts rate the stock positively with an average score of 7.04 out of 10.
Trip ifAnalyst consensus price target declines below $28, eliminating the upside margin.
- P4The data flags two value-trap signals: revenue declined -11.6% year-over-year in one measure while operating margin sits at just 1.5%, indicating the company is at risk of consuming its asset base faster than it creates value, which is a classic precursor to dilutive financing rounds.
Trip ifOperating margin declines to below -10% in any reported period, accelerating the value-trap trajectory.